Veru Inc
Veru Inc. is a U.S.-based biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases. Its pipeline centers on enobosarm, an oral selective androgen receptor modulator, and sabizabulin, an oral microtubule disruptor, with development activities directed from the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of enobosarm as an oral SARM to preserve muscle and bone while reducing fat in obesity treatment.
Development of sabizabulin for inflammation-driven cardiovascular risk reduction in stable coronary artery disease.
Customers
Veru does not sell a broad commercial product portfolio today; its primary counterparties are clinical investigators, research sites, regulators, and future healthcare buyers for approved medicines. If its candidates reach market, the end customers would be physicians, hospitals, and patients in obesity and cardiovascular disease settings.
Research sites, investigators, and CRO-like partners that support development of enobosarm and sabizabulin.
FDA and other agencies that evaluate clinical and safety data before any commercialization.
Potential prescribers for obesity and cardiovascular indications if the drug candidates are approved.
End users of the therapies, especially patients needing weight-loss support with lean-mass preservation or inflammation reduction.
Strategy
Veru’s strategy is to advance a small number of late-stage drug candidates with differentiated mechanisms in large cardiometabolic markets. The company is prioritizing clinical execution, regulatory progress, and eventual commercialization planning around enobosarm and sabizabulin.
Enobosarm is the company’s most visible obesity-related asset and targets a large unmet need.
Sabizabulin provides a second late-stage program and broadens the pipeline beyond obesity.
Any approved asset would require launch readiness, market access, and physician adoption.
Geography
Q2/2024Veru is headquartered in the United States and conducts its development work from there. Its drug candidates are intended for global pharmaceutical markets, with competition and regulatory pathways spanning North America, Europe, and other regions.
Share of the revenue the company reports by geography.
Risks
Veru faces the typical risks of a late-stage biopharmaceutical developer: clinical failure, regulatory delay, and commercialization uncertainty. It also competes against much larger pharmaceutical companies in obesity and cardiovascular disease, while needing external capital to fund development and operations.
- No current commercial revenue baseImpact: CriticalLikelihood: High
After the FC2 business sale, the company depends on future approvals to generate product revenue.
Exposure: Entire business model
- Clinical development riskImpact: HighLikelihood: High
Enobosarm and sabizabulin are still in development and may not demonstrate sufficient benefit-risk profiles.
Exposure: Pipeline assets
- Financing and dilution riskImpact: HighLikelihood: High
Development spending exceeds internal cash generation, so the company may need equity or debt financing.
Exposure: Corporate funding
- Competitive pressure in obesity and cardiometabolic marketsImpact: HighLikelihood: Medium
Major pharmaceutical companies and biotech firms have greater R&D, regulatory, and commercial resources.
Exposure: Enobosarm and sabizabulin programs
- Intellectual property enforcement riskImpact: MediumLikelihood: Low
Protecting enobosarm-related IP may require litigation that is expensive and uncertain.
Exposure: Patent estate
Accounting
Judgemental itemsClinical trial costs are a major operating expense and drive period-to-period volatility.
Impact: Affects operating loss and comparability across quarters
The company has reported changes in fair value of equity securities and derivative liabilities.
Impact: Can create non-cash gains or losses in earnings
Goodwill remains on the balance sheet and is tested against reporting-unit fair value.
Impact: Could lead to material non-cash impairment charges
The FC2 business sale and ENTADFI asset sale affect how results are presented.
Impact: Can separate legacy business results from continuing operations
Similar listed companies
Publicly listed companies with a comparable business focus.
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
iBio, Inc.
IBIO · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
BioVie Inc
BIVIW · Pharmaceutical Preparations
Vor Biopharma Inc.
VOR · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026